Elutia Inc.
ELUT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001708527
No open-market purchases or sales by Elutia Inc. insiders were filed in the last 90 days; 39 institutions reported holding it in 13F filings for Q2 2026, worth $13.8M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Elutia Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 17 | 17 | 0 |
| Shares | 3.34M | 3.33M | −6.74K (−0.2%) |
| Value | $23.6M | $24.0M | +$385.0K (+1.6%) |
New holders (2)
Institutions that held Elutia Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Tower Research Capital LLC (TRC) | 151 | $1.00K | 0.00% |
| Royal Bank of Canada | 34 | $0 | 0.00% |
Sold out (2)
Institutions that held Elutia Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Barclays PLC | 2,932 | $21.0K |
| Nisa Investment Advisors, LLC | 547 | $4.00K |